Harikumar Kaleeckal G, Pinon Delia I, Miller Laurence J
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona 85259, USA.
J Biol Chem. 2007 Oct 19;282(42):30363-72. doi: 10.1074/jbc.M702325200. Epub 2007 Aug 28.
Oligomerization of the Class II G protein-coupled secretin receptor has been reported, but the molecular basis for this and its functional significance have not been determined. In the current work, we have examined the possible contribution of each of the transmembrane (TM) segments of this receptor to its homo-oligomerization, using the method of competitive disruption screening for inhibition of receptor bioluminescence resonance energy transfer signal. TM IV was the only segment that was found to disrupt receptor bioluminescence resonance energy transfer. Evaluation of predicted interhelical and lipid-exposed faces of this TM segment demonstrated that its lipid-exposed face represented the determinant for oligomerization. This was further confirmed by mutagenesis of the intact secretin receptor. Morphological FRET was utilized to demonstrate that secretin receptor oligomerization occurred at the cell surface and that this oligomerization was disrupted by mutating Gly(243) and Ile(247), key residues within the lipid-exposed face of TM IV. Although disruption of the receptor oligomerization interface had no effect on secretin binding parameters, it reduced the ability of secretin to stimulate intracellular cAMP. This supports a clear functional effect of oligomerization of this receptor. Such an effect might be particularly relevant to clinical situations in which this receptor is overexpressed, such as in certain neoplasms.
已有报道称II类G蛋白偶联促胰液素受体可发生寡聚化,但其中的分子基础及其功能意义尚未明确。在当前研究中,我们采用竞争性破坏筛选法抑制受体生物发光共振能量转移信号,研究了该受体各跨膜(TM)区段对其同源寡聚化的可能作用。TM IV是唯一被发现可破坏受体生物发光共振能量转移的区段。对该区段预测的螺旋间和脂质暴露面进行评估表明,其脂质暴露面是寡聚化的决定因素。完整促胰液素受体的诱变进一步证实了这一点。利用形态学FRET证明促胰液素受体寡聚化发生在细胞表面,并且通过突变TM IV脂质暴露面内的关键残基Gly(243)和Ile(247)可破坏这种寡聚化。虽然破坏受体寡聚化界面不影响促胰液素结合参数,但它降低了促胰液素刺激细胞内cAMP的能力。这支持了该受体寡聚化具有明确的功能效应。这种效应可能与该受体过度表达的临床情况特别相关,例如在某些肿瘤中。